Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

ITM and RAD Sign Supply Agreement for n.c.a. Lutetium-177

Monday, May 19, 2025 1 min read
Key Takeaway: ITM and RAD have entered into a supply agreement for n.c.a. Lutetium-177, which is expected to improve the accessibility of this important radiopharmaceutical. This partnership signifies a step forward in the development and distribution of Lutetium-177 for therapeutic applications. The agreement may bolster both companies' positions in the radiopharmaceutical market.
Price reaction · baseline $4.3354 (2025-05-19T18:33:00.000Z) · hit during market hours · clean, no other RADX news in the window
day 0 close · peak
-0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • ITM and RAD have signed a supply agreement for Lutetium-177.
  • This agreement may enhance the availability of Lutetium-177 for therapeutic use.
  • The collaboration indicates a strategic partnership in radiopharmaceuticals.

Full Press Release Details

• Announcements
• Progress Report
• May 19, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• May 8, 2024
• Announcements
• June 22, 2022
• Announcements
• May 12, 2025
• Announcements
• August 27, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the purpose of the ITM and RAD agreement?

The agreement aims to enhance the supply of n.c.a. Lutetium-177 for therapeutic use.

What does n.c.a. stand for in this context?

n.c.a. stands for non-carrier added, indicating the purity of Lutetium-177.

How does this agreement benefit patients?

It is expected to improve the availability of Lutetium-177 for patients requiring treatment.

What companies are involved in this supply agreement?

The supply agreement involves ITM and RAD.

Tags: RADX Viatris Investor Conferences Healthcare Lutetium-177 ITM RAD radiopharmaceuticals supply agreement
Last updated: May 19, 2025